Meta Information
ID:sermorelin
Name:
Schema Version:AIM-2.0
Interactions
Target id:
/circadian/sleep
Target name:
Going to Sleep
Severity:
major
Interaction type:
requirement
Nature:
temporal
Temporal spacing:
Hours before target:
0.5
Hours after target:
null
Description:
Sermorelin is designed to amplify the large, natural pulse of growth hormone that occurs during the first few hours of deep, slow-wave sleep.
Actionable advice:
Administer the injection within 30 minutes of going to bed for the night.
Target id:
/dietary/meal
Target name:
Any Caloric Meal
Severity:
major
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2.5
Hours after target:
null
Description:
Elevated blood sugar and fatty acids from food intake trigger the release of somatostatin, a hormone that directly inhibits the pituitary's release of growth hormone, rendering Sermorelin ineffective.
Actionable advice:
Administer on a completely empty stomach, at least 2 to 3 hours after your last meal.
Target id:
/dietary/high-sugar-foods
Target name:
High-Sugar or High-Carbohydrate Foods
Severity:
major
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
3
Hours after target:
null
Description:
A spike in blood glucose is the most potent stimulus for somatostatin release, which will completely block the action of Sermorelin and natural growth hormone release.
Actionable advice:
Strictly avoid sugary foods or large carbohydrate meals for at least 3 hours before your injection.
Target id:
/condition/active-cancer
Target name:
Active Cancer / Malignancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Sermorelin increases levels of Insulin-like Growth Factor 1 (IGF-1), a potent growth factor that could theoretically promote the growth of existing tumors.
Actionable advice:
Do not use if you have an active malignancy; this is an absolute contraindication.
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The effects of Sermorelin on fetal development are unknown and could be harmful. It is strictly contraindicated during pregnancy.
Actionable advice:
Avoid completely if you are pregnant, planning to become pregnant, or suspect you might be pregnant.
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is not known if Sermorelin passes into breast milk or what its effects on a nursing infant might be. Use is contraindicated.
Actionable advice:
Avoid completely while breastfeeding.
Target id:
/class/somatostatin-analogs
Target name:
Somatostatin Analogs (e.g., Octreotide)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Somatostatin analogs are designed to block growth hormone release, directly and completely counteracting the entire purpose and mechanism of Sermorelin.
Actionable advice:
Do not use Sermorelin if you are taking a somatostatin analog; this is a direct contraindication.
Target id:
/class/corticosteroids
Target name:
Corticosteroids (e.g., Prednisone)
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Chronic use of high-dose glucocorticoids is known to suppress the HGH/IGF-1 axis, which will reduce the pituitary's ability to respond to Sermorelin.
Actionable advice:
Be aware that long-term corticosteroid therapy may significantly reduce the effectiveness of Sermorelin.
Target id:
/condition/thyroid-disorders
Target name:
Untreated Thyroid Disorders
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Normal thyroid hormone levels are required for an optimal pituitary response to GHRH; untreated hypothyroidism can significantly blunt Sermorelin's effectiveness.
Actionable advice:
Ensure your thyroid function is tested and optimized before and during therapy for best results.
Target id:
/condition/diabetes-mellitus
Target name:
Uncontrolled Diabetes Mellitus
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Chronically elevated blood glucose levels inhibit growth hormone secretion via somatostatin, which will counteract the intended effects of Sermorelin.
Actionable advice:
Work with your doctor to ensure good glycemic control, as high blood sugar will make Sermorelin less effective.
Target id:
/class/ghrps-ghrhs
Target name:
Other GH Secretagogues (e.g., Ipamorelin, CJC-1295)
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Combining a GHRH (like Sermorelin) with a GHRP (like Ipamorelin) can create a powerful synergistic effect, leading to a much greater HGH pulse than either agent alone.
Actionable advice:
May be combined with other secretagogues like Ipamorelin under medical supervision for an enhanced effect.
Target id:
/biomarker/igf-1
Target name:
IGF-1 (Insulin-like Growth Factor 1)
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Sermorelin's primary goal is to increase the body's production of IGF-1. Monitoring this biomarker is essential for gauging efficacy and safety.
Actionable advice:
Monitor IGF-1 levels at baseline and periodically during therapy to assess treatment efficacy and safety.
Target id:
/biomarker/fasting-glucose
Target name:
Fasting Glucose
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Growth hormone has a counter-regulatory effect on insulin and can slightly increase blood glucose levels in some individuals.
Actionable advice:
Periodically monitor fasting glucose to ensure therapy is not negatively impacting glycemic control.
Target id:
/intervention/resistance-training
Target name:
Resistance Training
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Resistance exercise is a natural stimulus for growth hormone release and can improve tissue sensitivity to IGF-1, enhancing the overall benefits of Sermorelin therapy.
Actionable advice:
Incorporate regular resistance training into your routine to complement the effects of Sermorelin.
Target id:
/class/anticholinergic-medications
Target name:
Anticholinergic Medications
Severity:
minor
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Theoretically, high-dose anticholinergic drugs may interfere with the neural pathways that regulate GHRH release, potentially blunting the response to Sermorelin.
Actionable advice:
The effect is likely minor, but be aware that strong anticholinergic drugs could slightly reduce Sermorelin's efficacy.